Torsemide Comparison With Furosemide for Management of Heart Failure - TRANSFORM-HF

Contribution To Literature:

The TRANSFORM-HF trial failed to show that torsemide was superior to furosemide in improving survival among patients treated for decompensated heart failure.

Description:

The goal of the trial was to evaluate furosemide compared with torsemide after hospitalization for decompensated heart failure.

Study Design

  • Randomized
  • Parallel
  • Open-label

Patients hospitalized with decompensated heart failure were randomized to furosemide (n = 1,428) vs. torsemide (n = 1,431) after discharge.

  • Total number of enrollees: 2,859
  • Duration of follow-up: 17.4 months
  • Mean patient age: 64 years
  • Percentage female: 37%

Inclusion criteria:

  • Patients hospitalized with decompensated heart failure regardless of ejection fraction

Principal Findings:

The primary outcome, all-cause mortality, occurred in 26.2% of the furosemide group vs. 26.1% of the torsemide group (p = 0.77).

Secondary outcomes:

  • All-cause mortality or hospitalization: 49.3% of the furosemide group vs. 47.3% of the torsemide group (p = 0.11)

Interpretation:

Among patients admitted with decompensated heart failure, post-discharge management with torsemide was not superior to furosemide. All-cause mortality was similar between treatment groups. Either furosemide or torsemide are acceptable options for diuresis among patients with heart failure.

References:

Presented by Dr. Robert J. Mentz at the American Heart Association Scientific Sessions, Chicago, IL, November 5, 2022.

Clinical Topics: Heart Failure and Cardiomyopathies, Statins, Acute Heart Failure

Keywords: AHA Annual Scientific Sessions, AHA22, Diuresis, Furosemide, Heart Failure, Patient Discharge, Stroke Volume, Torsemide


< Back to Listings